Evommune, Inc. (EVMN) Financial Ratios
3 years of historical data (2023–2025)
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
3.17
↑+21% vs avg
5yr avg: 2.63
30Y Low2.6·High2.6
ROE
-224.6%
+0% vs avg
5yr avg: -224.6%
30Y Low-225%·High-225%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EVMN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Evommune, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Market Cap | $652M | $540M | — | — |
| Enterprise Value | $610M | $498M | — | — |
| P/E Ratio → | -9.49 | — | — | — |
| P/S Ratio | 50.17 | 41.51 | — | — |
| P/B Ratio | 3.17 | 2.63 | — | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EVMN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| EV / Revenue | — | 38.28 | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
EVMN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Evommune, Inc. earns an operating margin of -623.6%. Operating margins have expanded from -757.0% to -623.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -224.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Gross Margin | 89.3% | 89.3% | 81.6% | 80.0% |
| Operating Margin | -623.6% | -623.6% | -1000.2% | -757.0% |
| Net Profit Margin | -529.8% | -529.8% | -954.4% | -681.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ROE | -224.6% | -224.6% | — | — |
| ROA | -45.8% | -45.8% | -84.4% | -41.4% |
| ROIC | -61.9% | -61.9% | -136.9% | — |
| ROCE | -63.6% | -63.6% | -113.4% | -50.2% |
EVMN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $44M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | -0.20 | — | — |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | -11581.57 | -11581.57 | -1963.94 | -586.12 |
Net cash position: cash ($44M) exceeds total debt ($2M)
EVMN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Evommune, Inc.'s current ratio of 8.57x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 11.67x to 8.57x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Current Ratio | 8.57 | 8.57 | 2.64 | 11.67 |
| Quick Ratio | 8.57 | 8.57 | 2.64 | 11.67 |
| Cash Ratio | 8.33 | 8.33 | 2.57 | 11.53 |
| Asset Turnover | — | 0.06 | 0.09 | 0.06 |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
EVMN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Evommune, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $32M | $30M | $30M |
Peer Comparison
Compare EVMN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EVMNYou | $652M | -9.5 | — | — | 89.3% | -623.6% | -224.6% | -61.9% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 ARDX | $1B | -22.3 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
 PRAX | $7B | -18.4 | — | — | — | — | -45.8% | -65.0% | — |
 RAPT | $296M | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
 KYMR | $7B | -22.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 REGN | $64B | 14.7 | 15.3 | 15.6 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ABBV | $398B | 94.8 | 16.3 | 22.3 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 LLY | $1.1T | 50.6 | 36.2 | 122.3 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 3 years · Updated daily
What if you invested $1,000 in EVMN 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in EVMN be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs EVMN Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationEVMN vs IMVT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Immunovant, Inc..
Compare NowEVMN — Frequently Asked Questions
Quick answers to the most common questions about buying EVMN stock.
What is Evommune, Inc.'s P/E ratio?
Evommune, Inc.'s current P/E ratio is -9.5x. This places it at the 50th percentile of its historical range.
What is Evommune, Inc.'s ROE?
Evommune, Inc.'s return on equity (ROE) is -224.6%. The historical average is -224.6%.
Is EVMN stock overvalued?
Based on historical data, Evommune, Inc. is trading at a P/E of -9.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Evommune, Inc.'s profit margins?
Evommune, Inc. has 89.3% gross margin and -623.6% operating margin.